NCT04016181Enrolling by invitation
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
To prospectively study novel blood and lung biomarkers of disease activity in patients with IPF and other interstitial lung disease with the aims of prognostic modelling and disease clustering
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 29 Mar 2019
- Start date
- 14 Jun 2007
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Edinburgh
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT04016181
What you commit to
- Study type: Observational
- Planned participants: 800
- From 14 Jun 2007 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- candidates not a suitable for enrolment or unlikely to comply with the requirements of this study, in the opinion of the investigator, will be excluded.
Who the study is looking for
- patients with interstitial lung disease attending the Edinburgh Lung Fibrosis service
Age in the registry: 18 years to 99 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.